Literature DB >> 24751333

Expression of CD90, CD96, CD117, and CD123 on different hematopoietic cell populations from pediatric patients with acute myeloid leukemia.

Antonieta Chávez-González1, Elisa Dorantes-Acosta2, Dafne Moreno-Lorenzana3, Antonio Alvarado-Moreno4, Lourdes Arriaga-Pizano5, Héctor Mayani3.   

Abstract

BACKGROUND AND AIMS: In trying to contribute to our knowledge on the biology of hematopoietic stem cells (HSC) and hematopoietic progenitor cells (HPC) from pediatric acute myeloid leukemia (AML), in the present study we analyzed the expression of four cell surface antigens relevant to human hematopoiesis-CD90, CD96, CD117, and CD123-in bone marrow from pediatric AML patients and normal control subjects.
METHODS: CD34(+) CD38(-) cells (enriched for HSC) and CD34(+) CD38(+) cells (enriched for HPC) were resolved on the basis of CD34 and CD38 expression. Concomitantly, expression of CD90 and CD96 or CD117 and CD123 was assessed by multicolor flow cytometry in each cell population.
RESULTS: CD90 and CD117 were expressed in a low proportion of CD34(+) CD38(-) and CD34(+) CD38(+) cells and no significant differences were observed between normal marrow and AML at diagnosis. In contrast, CD96(+) cells and CD123(+) cells were found at significantly higher levels in both cell populations from AML at diagnosis, as compared to normal marrow. Levels of both cell surface markers after treatment remained higher than in normal marrow. DISCUSSION: These results show an increased frequency of CD96(+) and CD123(+) cells within the CD34(+) cell population from pediatric AML; this is consistent with the findings reported previously for adult AML. Our study supports the notion that expression of such antigens should be explored for their use as markers for diagnosis and prognosis.
Copyright © 2014 IMSS. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD117; CD123; CD90; CD96; Hematopoietic progenitor cells; Hematopoietic stem cells; Pediatric acute myeloid leukemia

Mesh:

Substances:

Year:  2014        PMID: 24751333     DOI: 10.1016/j.arcmed.2014.04.001

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  12 in total

Review 1.  Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer.

Authors:  Antonieta Chavez-Gonzalez; Babak Bakhshinejad; Katayoon Pakravan; Monica L Guzman; Sadegh Babashah
Journal:  Cell Oncol (Dordr)       Date:  2016-09-27       Impact factor: 6.730

2.  Deciphering molecular heterogeneity in pediatric AML using a cancer vs. normal transcriptomic approach.

Authors:  Barbara Depreter; Barbara De Moerloose; Karl Vandepoele; Anne Uyttebroeck; An Van Damme; Eva Terras; Barbara Denys; Laurence Dedeken; Marie-Françoise Dresse; Jutte Van der Werff Ten Bosch; Mattias Hofmans; Jan Philippé; Tim Lammens
Journal:  Pediatr Res       Date:  2020-10-17       Impact factor: 3.756

3.  Long noncoding RNA, CCDC26, controls myeloid leukemia cell growth through regulation of KIT expression.

Authors:  Tetsuo Hirano; Ryoko Yoshikawa; Hironori Harada; Yuka Harada; Atsuhiko Ishida; Takeshi Yamazaki
Journal:  Mol Cancer       Date:  2015-04-19       Impact factor: 27.401

4.  Yi-qi-yang-yin-tang increases the sensitivity of KG1a leukemia stem cells to daunorubicin by promoting cell cycle progression and regulating the expression of PTEN, TOPOII and mTOR.

Authors:  Zhe-Xin Shi; Hong-Yu Li; Xiang-Dong Yang; Hong Gao; De-Guan Li; Wen-Hua Yang; Fang Yao; Li-Xiang Yan
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

Review 5.  Role of new Immunophenotypic Markers on Prognostic and Overall Survival of Acute Myeloid Leukemia: a Systematic Review and Meta-Analysis.

Authors:  A F O Costa; D L Menezes; L H S Pinheiro; A F Sandes; M A P Nunes; D P Lyra Junior; D M Schimieguel
Journal:  Sci Rep       Date:  2017-06-23       Impact factor: 4.379

6.  CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27kip1 signaling.

Authors:  Feifei Zhang; Xiaoye Liu; Chiqi Chen; Jun Zhu; Zhuo Yu; Jingjing Xie; Li Xie; Haitao Bai; Yaping Zhang; Xia Fang; Hao Gu; Chun Wang; Wei Weng; Cheng Cheng Zhang; Guo-Qiang Chen; Aibing Liang; Junke Zheng
Journal:  Haematologica       Date:  2017-01-25       Impact factor: 9.941

7.  Aberrant expression of CD133 and CD82 in patients with pediatric acute lymphoblastic leukemia and the clinical significance.

Authors:  Hongyan Ji; Li Chen; Yunpeng Dai; Xiaojun Sun; Xiuli Li; Qi Wang; Daoxin Ma; Dongdong Du; Ping Zhao; Yulin Wang
Journal:  Oncol Lett       Date:  2017-09-18       Impact factor: 2.967

Review 8.  Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.

Authors:  Christian M Schürch
Journal:  Front Oncol       Date:  2018-05-18       Impact factor: 6.244

9.  CBX8 and CD96 Are Important Prognostic Biomarkers of Colorectal Cancer.

Authors:  Xin Song; Tao Tang; Chaofeng Li; Xin Liu; Lei Zhou
Journal:  Med Sci Monit       Date:  2018-11-01

10.  CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping.

Authors:  Anne E Bras; Valerie de Haas; Arthur van Stigt; Mojca Jongen-Lavrencic; H Berna Beverloo; Jeroen G Te Marvelde; C Michel Zwaan; Jacques J M van Dongen; Jeanette H W Leusen; Vincent H J van der Velden
Journal:  Cytometry B Clin Cytom       Date:  2018-11-18       Impact factor: 3.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.